Labcorp–Illumina cancer pact targets wider access to genomic tests

Labcorp and Illumina have expanded their collaboration to enhance access to precision oncology testing. The initiative involves developing new IVD kits and comprehensive genomic profiling tests, generating clinical evidence for payer coverage, and exploring co-commercialization of FDA-authorized and approved assays. A joint study on over 7,600 NSCLC samples demonstrated the utility of genomic profiling in detecting actionable variants, reinforcing the clinical relevance of their efforts.